Intraoperative Bleeding and Transfusion Management

Intraoperative bleeding and transfusion management addresses the haemorrhage and coagulation disturbances that arise during cardiac and major vascular surgery, and the strategies used to limit blood loss and rationalize the use of blood products. In cardiac surgery the use of cardiopulmonary bypass and systemic anticoagulation makes bleeding a central perioperative concern, and patient blood management has become a structured discipline within it.

Definition

Intraoperative bleeding and transfusion management is the prevention, monitoring, and treatment of surgical and coagulopathic blood loss during an operation, together with the evidence-based decision to administer red cells and other blood components.

Scope

This topic covers the sources of perioperative bleeding in cardiothoracic surgery, the concept of patient blood management, antifibrinolytic and blood-conservation strategies, and the evidence on restrictive versus liberal transfusion thresholds. It is reference material describing how bleeding and transfusion are managed and studied, not procedural guidance for a specific operation.

Core questions

• Why is bleeding a particular concern in cardiac surgery?
• What is patient blood management and what does it aim to achieve?
• How do antifibrinolytic agents reduce surgical blood loss?
• What does the evidence say about restrictive versus liberal transfusion thresholds?

Key concepts

• Patient blood management
• Cardiopulmonary bypass-associated coagulopathy
• Antifibrinolytic therapy (e.g., tranexamic acid)
• Restrictive versus liberal transfusion threshold
• Blood conservation strategies
• Point-of-care coagulation testing

Mechanisms

Cardiac surgery disturbs haemostasis through several routes: systemic heparinization for cardiopulmonary bypass, contact of blood with the bypass circuit that activates platelets and the fibrinolytic system, haemodilution, and hypothermia. The result can be a multifactorial coagulopathy superimposed on surgical bleeding. Management combines surgical haemostasis with pharmacological and transfusion strategies. Antifibrinolytic drugs such as tranexamic acid inhibit the breakdown of formed clot and reduce blood loss. Patient blood management bundles preoperative optimization, intraoperative conservation, and evidence-based transfusion thresholds; randomized trials in cardiac surgery have compared restrictive and liberal red-cell strategies to define when transfusion is warranted.

Clinical relevance

These frameworks explain how blood loss is anticipated and how transfusion decisions are studied and structured in cardiothoracic surgery, which aids interpretation of the perioperative literature. The content describes strategies and evidence at a conceptual level; it is not a transfusion protocol for an individual patient, and specific thresholds and product choices are decisions for the responsible clinical team.

Epidemiology

Cardiac surgery is a major consumer of blood products, and bleeding requiring transfusion or reoperation is a recognized complication associated with adverse outcomes. Large randomized trials and society guidelines have characterized transfusion practice and the comparative effects of restrictive strategies in this population.

History

Blood conservation in cardiac surgery developed alongside cardiopulmonary bypass, with antifibrinolytic agents and structured guidelines emerging to reduce transfusion. The Society of Thoracic Surgeons and Society of Cardiovascular Anesthesiologists issued blood conservation guidelines, and large randomized trials in the 2010s — including comparisons of restrictive and liberal transfusion and trials of tranexamic acid — refined the evidence base.

Debates

Restrictive versus liberal red-cell transfusion in cardiac surgery

Randomized trials have tested whether withholding transfusion until a lower haemoglobin threshold is as safe as a more liberal approach; the balance of benefit and harm and the patient groups in whom it applies remain topics of ongoing study.

Key figures

• Victor A. Ferraris
• C. David Mazer
• Paul S. Myles

Seminal works

• ferraris-2011
• mazer-2017
• myles-2017

Frequently asked questions

Why does cardiopulmonary bypass increase bleeding risk?

Bypass requires systemic anticoagulation and exposes blood to the artificial circuit, which activates platelets and fibrinolysis and, together with haemodilution and hypothermia, can produce a coagulopathy that adds to surgical bleeding.

What is patient blood management?

It is a structured, evidence-based approach that combines minimizing blood loss, optimizing the patient's own blood, and using transfusion only when warranted, with the aim of improving outcomes and reducing unnecessary transfusion.